Rachel Haurwitz, Co-founder and CEO of Caribou Biosciences, discusses using CRISPR to engineer human immune cells to fight cancer. Topics include the journey of CRISPR from breakthrough to FDA approval, enhancing CRISPR's effectiveness, balancing affinity in CRISPR editing, challenges in CAR T-cell therapies for cancer, and reflections on career shifts and gene complexities.